2-Substituted Methyl Penam Derivatives for Resistant Strains
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current β-lactam antibiotics are often rendered ineffective by β-lactamase enzymes produced by microorganisms, necessitating the use of β-lactamase inhibitors to enhance their spectrum and duration of action, but existing inhibitors have limitations in potency and effectiveness against resistant strains.
Innovation Solution
Development of novel 2-substituted methyl penam derivatives that act as β-lactamase inhibitors, which can be combined with β-lactam antibiotics to broaden their efficacy against human and animal pathogens, including resistant strains, through specific chemical structures and preparation processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing β-lactamase inhibitors are used to enhance antibiotic spectrum, then the effectiveness against resistant strains is improved, but the potency and effectiveness limitations remain
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of β-lactamase inhibitors through various substitutions at positions R1, R2, R3, R4, R5, R6, R7, and R8 with different functional groups including halogens, alkyl groups, aryl groups, heterocyclic groups, and their combinations. These structural parameter changes result in compounds with enhanced potency and effectiveness against resistant bacterial strains compared to existing inhibitors.
2Reliability
If novel 2-substituted methyl penam derivatives are developed, then the β-lactamase inhibiting properties are enhanced, but the device complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex chemical structure into distinct substitutable positions (R1 through R8) around the core penam structure. This allows systematic modification of individual positions with specific functional groups to optimize β-lactamase inhibition while maintaining manageability in structure-activity relationship analysis and drug development.
3Adaptability or versatility
If combination therapy with β-lactam antibiotics is used, then the antibiotic spectrum is broadened, but the loss of time in treatment increases
Solution Approach 1:
The patent applies the intermediary principle by using β-lactamase inhibitor compounds as mediators that protect β-lactam antibiotics from degradation by β-lactamase enzymes. This allows the antibiotic combination to maintain effectiveness against resistant strains, thereby broadening the antibiotic spectrum while potentially reducing treatment duration by preventing enzyme-mediated inactivation of the antibiotic.
Data Source
Figure 1
AI summary
Novel 2-substituted methyl penam derivatives include the formula (I), their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their solvates, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them; wherein A = C or N; Het is a three- to seven-membered heterocyclic ring; R1 represents carboxylate anion, or -COOR4 where R4 represents hydrogen, carboxylic acid protecting group or a pharmaceutically acceptable salt; R2 and R3 may be same or different and independently represent hydrogen, halogen, amino, alkyl, protected amino, optionally substituted alkyl, alkenyl, alkynyl and the like; R represents substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, cycloalkyl, heterocyclyl or heterocyclylalkyl.